Showing results (241-250 of 321) with videos related to

Sort By:
Pageof 33
Rheumatology (Oxford, England)|October 6, 2019
Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5Désirée van der Heijde, Philip J Mease, Robert B M Landewé, et al.
Annals of the Rheumatic Diseases|September 17, 2025
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX studyPhilip J Mease, Christopher T Ritchlin, Laura C Coates, et al.
Annals of the Rheumatic Diseases|May 3, 2012
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsSusan Manzi, Jorge Sánchez-Guerrero, Joan T Merrill, et al.
Lancet (London, England)|March 18, 2020
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trialPhilip J Mease, Proton Rahman, Alice B Gottlieb, et al.
BMC Medical Genetics|November 23, 2012
Adult siblings with homozygous G6PC3 mutations expand our understanding of the severe congenital neutropenia type 4 (SCN4) phenotypeBridget A Fernandez, Jane S Green, Ford Bursey, et al.
ACR Open Rheumatology|March 7, 2023
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 StudiesDennis McGonagle, Iain B McInnes, Atul Deodhar, et al.
The Journal of Rheumatology|February 9, 2018
Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter StudyLihi Eder, Paula Harvey, Vinod Chandran, et al.
Rheumatology and Therapy|February 22, 2024
Work Productivity and General Health Through 2 Years of Guselkumab Treatment in a Phase 3 Randomized Trial of Patients With Active Psoriatic ArthritisJeffrey R Curtis, Iain B McInnes, Proton Rahman, et al.
Arthritis and Rheumatism|February 1, 2006
Association between a variation in LRCH1 and knee osteoarthritis: a genome-wide single-nucleotide polymorphism association study using DNA poolingTim D Spector, Richard H Reneland, Steven Mah, et al.
Clinical Rheumatology|March 13, 2024
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritisProton Rahman, Iain B McInnes, Atul Deodhar, et al.
Pageof 33